Home » Topics » BioWorld Science

BioWorld Science
RSS

FORMA Therapeutics identifies new HDAC6 inhibitors

May 13, 2019

OliX expands ocular disease pipeline with new OLX-304A program in retinitis pigmentosa

May 13, 2019

EnGeneIC initiates phase I/IIa study of EDV-based therapeutic in advanced pancreatic cancer

May 13, 2019

Impaired placental function linked to neurodevelopmental disorders

May 13, 2019

Urinary NT-proBNP a pulmonary hypertension marker in preterm infants with bronchopulmonary dysplasia

May 10, 2019

Liver chats with fat via serum protein GPNMB

May 10, 2019

Pooled safety analyses of global roxadustat phase III program confirm CV safety

May 10, 2019

BioCryst completes phase I study of intravenous galidesivir in healthy subjects

May 10, 2019

Mustang announces new phase I trial of CAR T-cell therapy for multiple myeloma

May 10, 2019

Aptose begins phase Ia/Ib study of CG-806 in CLL, SLL and NHL

May 10, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 31, 2025
Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal
BioWorld Science
As companies continually search for next-generation obesity prospects, one of the leaders in the disease space, Novo Nordisk A/S, has obtained an exclusive...
Corcept looks to NDA following strong phase III ovarian cancer data
BioWorld
Relacorilant, a cortisol modulator from Corcept Therapeutics Inc., produced new and strong phase III results in treating platinum-resistant ovarian cancer. The...
Otsuka submits first BLA to FDA for sibeprenlimab in IgAN
BioWorld
Otsuka Pharmaceutical Development & Commercialization Inc. filed its BLA with the U.S. FDA for sibeprenlimab to treat immunoglobulin A nephropathy (IgAN). The...